Mankind Pharma Ltd. (IN:MANKIND)
:MANKIND
MANKIND Stock Chart & Stats
₹2202.55
-₹40.15(-1.38%)
At close: 4:00 PM EST
₹2202.55
-₹40.15(-1.38%)
Day’s Range― - ―
52-Week Range₹1,909.90 - ₹2,726.75
Previous CloseN/A
Volume302.66K
Average Volume (3M)10.08K
Market Cap
₹842.31B
Enterprise Value₹920.30B
Total Cash (Recent Filing)₹31.05B
Total Debt (Recent Filing)₹83.69B
Price to Earnings (P/E)55.5
Beta0.52
Next Earnings
Jun 02, 2026EPS Estimate
10.34Next Dividend Ex-DateN/A
Dividend Yield0.04%
Share Statistics
EPS (TTM)12.50
Shares Outstanding412,828,340
10 Day Avg. Volume5,924
30 Day Avg. Volume10,081
Financial Highlights & Ratios
PEG Ratio16.80
Price to Book (P/B)6.94
Price to Sales (P/S)8.15
P/FCF Ratio50.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,800.00Price Target Upside27.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)57.78
Revenue Forecast (FY)₹159.59B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line expansion of ~18% year-over-year indicates durable demand for Mankind’s branded formulations and effective commercial execution. Over a 2–6 month horizon this growth supports reinvestment capacity, expands scale benefits, and underpins long-term market share gains across therapy areas.
High Margins / Operational EfficiencyVery strong gross and healthy operating margins reflect pricing power, favorable product mix, and manufacturing efficiency. These margin levels provide a structural cushion versus competitors and support ongoing R&D, marketing investment, and free cash flow generation over the medium term.
Cash Flow StrengthConsistent free cash flow growth and OCF exceeding net income signal high cash conversion and resilient cash generation. Strong cash yields flexibility to fund capex, M&A or shareholder returns without levering the balance sheet, supporting stability across business cycles.
Bears Say
Declining EPSA notable EPS decline despite revenue growth suggests rising costs, margin pressure in parts of the business, or non-operating impacts. Persisting negative EPS trends can weaken per-share returns, limit retained-earnings reinvestment, and constrain long-term shareholder value creation.
Domestic Revenue ConcentrationHeavy dependence on the Indian domestic market concentrates regulatory, pricing, and demand risks regionally. Any adverse policy shifts, generic pricing pressure, or local demand slowdowns could have outsized effects on revenue and profitability absent greater geographic diversification.
Branded Generics Competition & Regulatory RiskThe branded generics model faces structural price competition and regulatory scrutiny that can erode long-term pricing power. Sustained regulatory changes or intensified rival pricing could pressure margins and require higher marketing or compliance spend, reducing durable profitability.
Mankind Pharma Ltd. News
MANKIND FAQ
What was Mankind Pharma Ltd.’s price range in the past 12 months?
Mankind Pharma Ltd. lowest stock price was ₹1909.90 and its highest was ₹2726.75 in the past 12 months.
What is Mankind Pharma Ltd.’s market cap?
Mankind Pharma Ltd.’s market cap is ₹842.31B.
When is Mankind Pharma Ltd.’s upcoming earnings report date?
Mankind Pharma Ltd.’s upcoming earnings report date is Jun 02, 2026 which is in 54 days.
How were Mankind Pharma Ltd.’s earnings last quarter?
Mankind Pharma Ltd. released its earnings results on Feb 03, 2026. The company reported ₹12.5 earnings per share for the quarter, beating the consensus estimate of ₹12.038 by ₹0.462.
Is Mankind Pharma Ltd. overvalued?
According to Wall Street analysts Mankind Pharma Ltd.’s price is currently Undervalued.
Does Mankind Pharma Ltd. pay dividends?
Mankind Pharma Ltd. pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.04%. See more information on Mankind Pharma Ltd. dividends here
What is Mankind Pharma Ltd.’s EPS estimate?
Mankind Pharma Ltd.’s EPS estimate is 10.34.
How many shares outstanding does Mankind Pharma Ltd. have?
Mankind Pharma Ltd. has 412,828,340 shares outstanding.
What happened to Mankind Pharma Ltd.’s price movement after its last earnings report?
Mankind Pharma Ltd. reported an EPS of ₹12.5 in its last earnings report, beating expectations of ₹12.038. Following the earnings report the stock price went up 4.296%.
Which hedge fund is a major shareholder of Mankind Pharma Ltd.?
Currently, no hedge funds are holding shares in IN:MANKIND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mankind Pharma Ltd.
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.
MANKIND Stock 12 Month Forecast
Average Price Target
₹2,800.00
▲(27.13% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Cipla Ltd
―
Lupin Limited
―
Torrent Pharmaceuticals Ltd
―
Zydus Lifesciences Limited
―